For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- DSP to Set Up New Anticancer Drug Sales Company in US, Eyes Launch of BBI608
October 10, 2013
- Kaketsuken Submits 1st Japan-Made Hemophilia Inhibitor Treatment for Approval
October 9, 2013
- Takeda’s Norovirus Vaccine Misses Primary Endpoint in PI/II, but Reduces Vomiting, Diarrhea
October 9, 2013
- Chugai Files NDA for ALK Inhibitor Alectinib in Japan for NSCLC
October 9, 2013
- Onychomycosis Treatment Efinaconazole Licensed from Kaken Approved in Canada
October 9, 2013
- Astellas, US Biotech Venture to Collaborate on Mitochondrial Disease Therapies
October 8, 2013
- Quintiles Aims to Expand Business in Japan with More Employees: CEO
October 8, 2013
- Ethical Drug Sales Up 0.7% in August: Crecon Report
October 8, 2013
- 3 Combination Drugs for Asthma, COPD Get Approval to Fuel Competition; NHI Price Listing Expected in November
October 7, 2013
- Novartis AG Pharma Division Head Supports Ministry Panel’s Diovan Investigation Interim Report, Refuses to Comment on Whether Ads Were Exaggerated
October 7, 2013
- Nippon Shinyaku, Pfizer Japan Sign Deal for Promotional Activities for Tramal
October 7, 2013
- Novartis Japan Execs Face 30% Pay Cut amid Diovan Scandal, Compliance Advisory Board to Be Set Up
October 4, 2013
- Mundipharma Initiates Clinical Study of PTCL Treatment Pralatrexate in Japan
October 4, 2013
- Takeda, Tri-I TDI Conclude Research Deal
October 4, 2013
- Number of MRs Down Slightly to 63,846 as of March 2013; Are We Entering an Age of Decline for MRs?
October 4, 2013
- Nichi-Iko, South Korean Biotech Firm Partner Up on Biosimilar Business
October 3, 2013
- Nihon Chouzai to Increase Its Generic Portfolio to 1,000 in 2 Years: President Mitsuhara
October 3, 2013
- Asahi Kasei Pharma, Vernalis Sign Joint Research Agreement for New Drug Discoveries for Autoimmune Diseases
October 3, 2013
- Kissei, JCR to Jointly Develop Nesp Biosimilar
October 2, 2013
- Another Administrative Action Taken Against MTPC on Medway Injection; 3rd in 4 Years
October 2, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…